Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman

Hagens Berman is continuing its investigation into Aardvark Therapeutics (AARD) after the FDA placed a clinical hold on its lead drug candidate, ARD-101, for Prader-Willi Syndrome. This follows a previous 56% stock drop when Aardvark paused its HERO trial due to serious safety risks, specifically "reversible cardiac observations." The firm is exploring whether Aardvark misled investors regarding ARD-101's safety, efficacy, and communications with the FDA, given the significant stock declines after these announcements.